Chaturvedi, N, LK Stevens, JH Fuller, et al. :Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. .Diabetologia 44 ( suppl 2:):65S. ,2001. .
Jeffcoate, WJ and KG Harding. :Diabetic foot ulcers. .Lancet 361::1545. ,2003. .
Jeffcoate, WJ . :The incidence of amputation in diabetes. .Acta Chir Belg 105::140. ,2005. .
Tanaka, A, T Nagate, and H Matsuda. :Acceleration of wound healing by gelatin film dressings with epidermal growth factor. .J Vet Med Sci 67::909. ,2005. .
Kwon, YB, HW Kim, DH Roh, et al. :Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat. .J Vet Sci 7::105. ,2006. .
Laato, M, VM Hahari, J Niinikoski, et al. :Epidermal growth factor increases collagen production in granulation tissue by stimulation of fibroblast proliferation and not by activation of procollagen genes. .Biochem J 247::385. ,1987. .
Tsang, MW, WK Wong, CS Hung, et al. :Human epidermal growth factor enhances healing of diabetic foot ulcers. .Diabetes Care 26.:1856. ,2003. .
Hong, JP, HD Jung, and YW Kim. :Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. .Ann Plast Surg 56::394. ,2006. .
Hoffman, AS . :Hydrogels for biomedical applications. .Adv Drug Del Rev 43::3. ,2002. .
Peppa, M, H Brem, P Ehrlich, et al. :Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. .Diabetes 52::2805. ,2003. .
Galeano, M, D Altavilla, D Cucinotta, et al. :Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. .Diabetes 53::2509. ,2004. .
Krajewska, M, S Krajewski, JI Epstein, et al. :Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. .Am J Pathol 148::1567. ,1996. .
Winter, GD . :Formation of scab and the rate of epithelialization of superficial wounds in the skin of the young domestic pig. .Nature 193::293. ,1962. .
Hanna, JR and JA Giacopelli. :A review of wound healing and wound dressing products. .J Foot Ankle Surg 36::2. ,1997. .
Ovington, LG . :Advances in wound dressings. .Clin Dermatol 25::33. ,2007. .
Stashak, TS and E Farstvedt. :Update on wound dressings: indications and best use. .Clin Tech Equine Pract 3::148. ,2004. .
Repertinger, SK, E Campagnaro, J Fuhrman, et al. :EGFR enhances early healing after cutaneous incisional wounding. .J Invest Dermatol 123::982. ,2004. .
Knott, AW, RJ Juno, MD Jarboe, et al. :EGF receptor signaling affects bcl-2 family gene expression and apoptosis after massive small bowel resection. .J Pediatr Surg 38::875. ,2003. .
Puolakkainen, PA, DR Twardzik, JE Ranchalis, et al. :The enhancement in wound healing by transforming growth factor-β 1 (TGF-β 1) depends on the topical delivery system. .J Surg Res 58::321. ,1995. .
Hori, K, C Sotozono, and J Hamuro. :Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing. .J Control Release 118::169. ,2007. .
We sought to develop new recombinant human epidermal growth factor (rhEGF)–containing hydrogels and to investigate their biological activity and therapeutic effects on wound healing in diabetic rats.
Levels of rhEGF released from hydrogels were measured by enzyme-linked immunosorbent assay. The cellular proliferating activity of released rhEGF was evaluated by MTT assay. Fifty-six wounded diabetic rats were randomly divided into four groups with different topical treatment daily. The therapeutic effects were evaluated by wound area measurement, histologic analysis, immunohistochemical assessment of proliferating cell nuclear antigen and B-cell lymphoma/leukemia-2, and Western blotting of EGF receptor.
The rhEGF released from the hydrogel matrix kept its bioactivity on stimulating proliferation of the BALB/c3T3 cell line. Wound closure rates on postoperative day 14 were 75.8% in the negative control group, 82.83% in the group treated with hydrogel matrix, 85.87% in the group treated with rhEGF-containing hydrogel, and 81.18% in the group treated with rhEGF solution. Compared with hydrogel matrix, rhEGF-containing hydrogel had an additional effect on induction of EGF receptor expression (P < .05). Compared with negative controls, protein expression of B-cell lymphoma/leukemia-2 was higher in the rhEGF-containing groups (P < .05). Proliferating cell nuclear antigen was induced at its highest level on day 7 in the rhEGF-containing hydrogel–treated group (P < .05).
These data from in vitro release and diabetic animal models highlight the efficacy of hydrogels as a controlled releasing system for topical application of EGFs. The rhEGF-containing hydrogel we developed holds the merits of prolonged and sustained releasing of bioactive rhEGF and therapeutic potential in enhancing diabetic wound healing. (J Am Podiatr Med Assoc 102(2): 89–98, 2012)